[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363339-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363339-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapeutic-potential-of-tertiary-lymphoid-structures-in-breast-cancer-review","Therapeutic potential of tertiary lymphoid structures in breast cancer - Review","","Tertiary lymphoid structures (TLS) are organized immune aggregates in the tumor microenvironment linked to better prognosis and improved immunotherapy response in breast cancer, yet their functional duality and therapeutic value need clarification. This review synthesizes current knowledge on TLS in breast cancer, covering molecular mechanisms of formation and maturation, their anti-tumor immune functions, prognostic significance, and emerging strategies for therapeutic targeting. Mature functional TLS mediate adaptive anti-tumor immunity, while immature TLS may act oppositely. TLS features can predict response to immune checkpoint inhibitors, supporting TLS-inducing therapeutic approaches.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapeutic-potential-of-tertiary-lymphoid-structures-in-breast-cancer-review/363339/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapeutic-potential-of-tertiary-lymphoid-structures-in-breast-cancer-review/363339.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are tertiary lymphoid structures (TLS) in breast cancer?","Question",{"text":63,"@type":64},"TLS are organized immune aggregates within the tumor microenvironment that show similarities to secondary lymphoid organs, including T/B cell zones, germinal centers, dendritic cells, and high endothelial venules.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do mature and immature TLS differ in their effects?",{"text":68,"@type":64},"Mature and functional TLS are key mediators of adaptive anti-tumor immunity, whereas immature TLS may have opposing or pro-tumor effects.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is TLS considered important for prognosis and immunotherapy response?",{"text":72,"@type":64},"TLS presence and characteristics have strong prognostic value and can predict response to immune checkpoint inhibitors, including through their maturation-linked functional state.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363339,1790181993,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Molecular Medicine rePorTS 33: 177, 2026  \nTherapeutic potential of tertiary lymphoid structures in breast cancer (Review)  \nLIANGXIAO ZHU 1* , MeiGui li2* , FENG LIU3 and FENGHOU GAO3  \n1Clinical Laboratory, Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai, Shanghai 201999, P.R. China; 2Department of Oncology, Hainan Western Central Hospital, Danzhou, Hainan 571700, P.R. China; 3department of oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, P.R. China  \nReceived November 3, 2025; Accepted March 9, 2026  \nDOI: 10. 3892/mmr.2026.13887  \nAbstract. Tertiary lymphoid structures (TlS) are organized immune aggregates within the tumor microenvironment that are associated with improved prognosis and immunotherapy response in breast cancer, yet their functional duality and therapeutic potential require further clarification. The present review comprehensively summarizes current knowledge on TlS in breast cancer, focusing on their molecular mecha‑ nisms of formation and maturation, multifaceted functions in anti‑tumor immunity, established prognostic importance and emerging strategies for therapeutic targeting. The present study highlights that mature and functional TlS are key mediators of adaptive anti‑tumor immunity, whereas immature TlS may have opposing effects. Their presence and characteristics hold strong prognostic value and can predict response to immune checkpoint inhibitors. Consequently, therapeutic strategies aimed at inducing or enhancing TlS represent a promising  \ndirection for breast cancer immunotherapy. However, further research is needed to elucidate the precise regulatory networksand translate TLS‑focused strategies into clinical practice.  \nContents  \n1. Introduction  \n2. Literature search  \n3. Formation of TLS in breast cancer  \n4. Maturation of TLS in breast cancer  \n5. Function of TLS in breast cancer  \n6. Prognostic importance of TLS in breast cancer  \n7. Potential of TLS as a therapeutic target for breast cancer  \n8. Discussion and future perspectives  \nCorrespondence to: Dr Feng Liu or Dr Fenghou Gao, department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 280 Mo‑He Road, Shanghai 201999, P.R. China  \ne‑[mail: nuanliu@126.com](mail: nuanliu@126.com)  \nE‑mail: [fenghougao@163.com](fenghougao@163.com)  \n*contributed equally  \nAbbreviations: TLS, tertiary lymphoid structures; TME, tumor microenvironment; GC, germinal center; DC, dendritic cell; HEV, high endothelial venule; LTi, lymphoid tissue inducer; LTo, lymphoid tissue organizer; Tfh cell, follicular helper T cell; LTβr, lymphotoxin‑β receptor; LTα , lymphotoxin‑α; NK, natural killer; FDC, follicular dendritic cell; Treg, regulatory T cell; Trm, tissue‑resident memory T cell; TIL, tumor‑infiltrating lymphocyte; OS, overall survival; DFS, disease‑free survival; TNBC, triple‑negative breast cancer; ICI, immune checkpoint inhibitor; PNAd, peripheral node addressin; HEC, high endothelial cell; SHM, somatic hypermutation; CSR, class switch recombination; CAFs, cancer‑associated fibroblasts  \nKey words: tertiary lymphoid structures, breast cancer, tumor microenvironment, tumor immunity, targeted therapy  \n1. Introduction  \nBreast cancer remains a notable global health challenge, being the most commonly diagnosed cancer and a leading cause of cancer‑related mortality among women worldwide‑in 2022, this burden translated to 2.3 million new cases (representing 25% of all cancers in women) and 670,000 deaths (repre‑ senting 16% of all cancer‑related deaths in women) (1). Despite advances in early detection and multimodal therapies, meta‑ static disease and therapeutic resistance continue to drive poor outcomes, underscoring the need for novel treatment strate‑ gies, particularly those that harness the immune system, such as immune checkpoint inhibitors or adoptive cell therapies, to enhance antitumor immunity. ","cbCaigfY8djTQukW","https://ap.wps.com/l/cbCaigfY8djTQukW","pdf",3114410,"English","# Introduction\n## Literature search\n## Formation of TLS in breast cancer\n## Maturation of TLS in breast cancer\n## Function of TLS in breast cancer\n## Prognostic importance of TLS in breast cancer\n## Potential of TLS as a therapeutic target for breast cancer\n## Discussion and future perspectives","[{\"question\":\"What are tertiary lymphoid structures (TLS) in breast cancer?\",\"answer\":\"TLS are organized immune aggregates within the tumor microenvironment that show similarities to secondary lymphoid organs, including T/B cell zones, germinal centers, dendritic cells, and high endothelial venules.\"},{\"question\":\"How do mature and immature TLS differ in their effects?\",\"answer\":\"Mature and functional TLS are key mediators of adaptive anti-tumor immunity, whereas immature TLS may have opposing or pro-tumor effects.\"},{\"question\":\"Why is TLS considered important for prognosis and immunotherapy response?\",\"answer\":\"TLS presence and characteristics have strong prognostic value and can predict response to immune checkpoint inhibitors, including through their maturation-linked functional state.\"}]","Therapeutic potential of tertiary lymphoid structures in breast cancer - Review | PDF",1790150850,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7dfab13a905afa4a1ea4dc1f1ed62def.webp",983,1357,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd3b5350f792fb67d52c8566c0de74b6.webp",982,1356,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df23ac55c0ade8ff10945491f44f043f.webp",981,1354,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b1b36a51a7ea89d9e7feb4a0ed26ef6.webp",980,1353]